DeepMed Research

Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia

Phase 3

Recruiting

Conditions: Sickle Cell Disease, Thalassemia

Interventions: Drug: Etavopivat A
Drug: Etavopivat B

First Posted Date: 2024-09-24

Last Posted Date: 2025-05-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 325

Registration Number: NCT06609226

Locations: 🇺🇸
Univ of Alabama Birmingham, Birmingham, Alabama, United States
🇺🇸
Phoenix Children's Hsptl, Phoenix, Arizona, United States
🇺🇸
Children's Hospital Los Angeles - Endocrinology, Los Angeles, California, United States

and more 90 locations

A Disease Area Study on the Awareness and Perceptions of Systemic Inflammation and hsCRP as a biomARKer in Patients With ASCVD and CKD in China Among Cardiologists and Nephrologists

Completed

Conditions: Atherosclerotic Cardiovascular Disease (ASCVD)
Chronic Kidney Disease (CKD)

Interventions: Other: No treatment given

First Posted Date: 2024-09-19

Last Posted Date: 2025-01-07

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1500

Registration Number: NCT06589791

Locations: 🇨🇳
Novo Nordisk Shanghai Pharmaceuticals Co., Ltd, Shanghai, China

Research Study in Japan to Compare Dasiglucagon With Glucagon in Treating Very Low Levels of Blood Sugar in Asian Adults With Type 1 Diabetes and Testing of Dasiglucagon for the Same Condition in Japanese Adolescents

Phase 1

Recruiting

Conditions: Diabetes Mellitus, Type 1

Interventions: Drug: Dasiglucagon
Drug: Glucagon

First Posted Date: 2024-09-19

Last Posted Date: 2024-12-16

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 38

Registration Number: NCT06588504

Locations: 🇯🇵
Hakata Clinic, Fukuoka, Japan

Patient Preference Study in Type-2 Diabetes Mellitus: Discrete Choice Experiment (DCE) to Support Novo Nordisk's Long-Acting Insulin

Completed

Conditions: Type-2 Diabetes Mellitus (T2DM)

Interventions: Other: No treatment given

First Posted Date: 2024-09-12

Last Posted Date: 2024-09-12

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 513

Registration Number: NCT06592950

Locations: 🇩🇰
Novo Nordisk, Søborg, Denmark

A Research Study Looking at a Single Dose of Etavopivat in Healthy Chinese Participants

Phase 1

Completed

Conditions: Healthy Volunteers
Sickle Cell Disease
Thalassemia

Interventions: Drug: Etavopivat

First Posted Date: 2024-09-03

Last Posted Date: 2024-12-16

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 24

Registration Number: NCT06581627

Locations: 🇨🇳
Beijing Hospital, Beijing, Beijing, China

A Research Study on How NNC0638-0355, a New Medicine, Works in People Living With Overweight or Obesity

Phase 1

Recruiting

Conditions: Overweight
Obesity

Interventions: Drug: Placebo (NNC0638-0355)
Drug: NNC0638-0355

First Posted Date: 2024-08-29

Last Posted Date: 2024-10-03

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 88

Registration Number: NCT06577766

Locations: 🇺🇸
ICON, San Antonio, Texas, United States

Study for Turoctocog Alfa Treatment Regimen in Iraqi Haemophilia A Patients

Recruiting

Conditions: Congenital Bleeding Disorder
Haemophilia A

Interventions: Drug: Turoctocog alfa

First Posted Date: 2024-08-28

Last Posted Date: 2025-04-11

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 900

Registration Number: NCT06574984

Locations: 🇮🇶
National centre for Hamophilia, Baghdad, Iraq
🇮🇶
Basrah Haemoplhilia centre, Basrah, Iraq
🇮🇶
Hilla Haemophilia centre, Hilla, Iraq

and more 2 locations

STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss

Phase 4

Recruiting

Conditions: Obesity

Interventions: Drug: Semaglutide

First Posted Date: 2024-08-26

Last Posted Date: 2025-05-08

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 500

Registration Number: NCT06571383

Locations: 🇺🇸
Neighborhood Healthcare, Escondido, California, United States
🇺🇸
Clinical Neuroscience Solution, Orlando, Florida, United States
🇺🇸
TMH Physician Partners Endo, Tallahassee, Florida, United States

and more 87 locations

A Research Study of How Safe a New Medicine Called NNC0519 0130 is and to Test Its Effect in People Living With Excess Body Weight With or Without Type 2 Diabetes

Phase 1

Active, not recruiting

Conditions: Diabetes Mellitus, Type 2
Obesity

Interventions: Drug: NNC0519-0130
Drug: Placebo

First Posted Date: 2024-08-22

Last Posted Date: 2025-04-10

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 64

Registration Number: NCT06567041

Locations: 🇩🇪
Parexel International GmbH, Berlin, Germany

A Research Study Looking Into Blood Levels of the Medicine NNC0487-0111 in the Body and How Well it is Tolerated in Participants With Reduced Kidney Function and Normal Kidney Function

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2
Obesity
Overweight

Interventions: Drug: NNC0487-0111

First Posted Date: 2024-08-19

Last Posted Date: 2025-03-30

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 42

Registration Number: NCT06559527

Locations: 🇩🇪
Charité Research Organisation GmbH, Berlin, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy